Association of clonal hematopoiesis and AITL: genetic evidence for stem cell origin, etiology and prediction of secondary hematologic malignancy in AITL

Shuhua Cheng¹, Wei Zheng², Giorgio Inghirami¹, Wayne Tam^{1*}

¹Department of Pathology and Laboratory Medicine, ² Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY 10021

Supplemental Text

Fig.1A: 6 illustrative cases in which common mutated HSC developed into CH and AITL or PTCL-NOS

In Patient #1, identical TET2 and DNMT3A somatic mutations, p. E1089fs and p.F791L, were identified both in CH (VAFs: 48.39%, 34.62%) and in the neoplastic T cells in the diagnostic LN specimen (VAFs: 36.87%, 27.59%) (Figure 1A). The other four pathogenic variants, TET2 p.Q743*, RHOA p.G17V, IDH2 p.R172T and PTPRF p.R654H, were detected at high VAFs in the LN but at much lower VAFs in the BM (Figure 1A). These results demonstrate that the latter four mutations are likely acquired at a later time point during AITL development (late mutations) and the low-VAF variants detected in the BM represent minimal involvement in the BM and not CH. Patient #4 had no overt evidence of a myeloid neoplasm in the BM while diagnosed with AITL, and had 2.1% bone marrow involvement by AITL according to immunophenotypic and gene rearrangement studies. The T cell NGS panel identified 7 pathogenic mutations in the primary lymphoma, of which 6 were also found in the matched BM. The allelic burden of the two mutations with the highest VAFs (DNMT3A p. Q678*, VAF=6.22%; ATP1A3 p.V216M, VAF=4.47%), were 2 to 3 times that of the estimated tumor burden (2.1%) in the BM, suggesting that DNMT3A p. Q678* and ATP1A3 p.V216M were not only present in the neoplastic T-cells but also associated with CH. The other 5 mutations, including RHOA p.G17V and IDH2 p. R172G, were found at the VAFs ranging from 0% to 1.5% in the BM, consistent with lymphoma involvement rather than CH. These results suggest that these 5 mutations were acquired subsequent to the CH-associated mutations described above. Interestingly, sequencing a relapsed lymphoma specimen from this case identified only one mutation DNMT3A p. Q678*. This mutation information in the relapsed lymphoma helps clarify the clonal architecture of both the primary AITL and CH. First, it suggests that the primary AITL harbored two clones, a dominant clone with ATP1A3, DLGAP3, TET2, RHOA and IDH2 mutations, and a minor clone with DNMT3A mutation, the latter being the precursor clone for relapse. Second, it also implies that there are 2 clones in CH, one associated with the DNMT3A mutation and the other with the ATP1A3 mutation. In Patient #10, the CH-associated variant shared between the primary lymphoma and the matched BM, TET2 p. N1484K, was identified at high allelic burden in both the lymphoma and BM samples (VAFs in LN vs BM, 47.33% vs 38.26%,). Another TET2 mutation, p. D1378G, was also identified in the both the LN and the BM, at VAFs of 16.89% and 0.32% respectively. The large difference of the VAF in the BM of the two TET2 mutations suggests that they may belong to different HSC clones, each of which has markedly different CH contribution, or the TET2 p.D1378G mutation was acquired subsequent to the TET2 p.N1484K mutation as a subclonal mutation in the HSC. The other 3 mutations: TET2 p.V415fs, RHOA p.G17V and IDH2 p.R172T were present exclusively in the lymphoma sample. In patient #29, the DNMT3A R882H hot-spot mutation was shared at high VAFs in both the lymphoma and BM (46% and 35.6%), consistent with a CH-associated mutation, while the other 4 mutations detected in the LN was present in the BM at low VAFs, consistent with BM involvement by T-cell lymphoma. Interestingly, both the TET2 N1484K mutation in patient #10 and the DNMT3A R882H mutation in patient #29 were present in the primary lymphomas at a VAF of close to 50%, about 3-4 times the allelic fractions of other mutations identified in the LN. This finding implies the presence of these mutations in almost the entire cell population in the LN. However, based on immunomorphologic evaluation and the VAF of the other mutations identified in the LN, the tumor burden in the LN for these two cases is about 20-40%. This raises the possibility that besides the neoplastic T cells, reactive lymphocytes in these two cases might also harbor the CH-associated mutations.

In the two PTCL-NOS cases (#2 and #18), we observed similar findings as described above for AITL (**Fig. 1A**). Patient #2 showed eosinophilia with 1.5% neoplastic T cells involvement in the BM. Two pathogenic *STAT3* mutations were identified. One could be considered a CH-associated mutation (*STAT3* p.Y657_K658insALL, VAFs in LN vs BM, 21.61% vs 8.34%) since its VAF is considerably higher than the estimated percentage of tumor involvement in the BM. The other is most likely PTCL-NOS-related mutation (*STAT3* p.W474*). This *STAT3* nonsense mutation had the allelic burden of 18.33% in the primary lymphoma but was present at much lower level (VAF = 2%) in the matched PB, in line with the estimated tumor burden. Patient #18 presented mildly hypercellular marrow with mild granulocytic hyperplasia while diagnosed with PTCL-NOS and had no involvement in the BM per the overall pathologic studies. The NGS target panel identified a splice mutation in *TET2* (c.3501-1G>A) and a missense mutation in *SETX* (p. Y2258D) shared between CH and PTCL-NOS. Two mutations (*TP53* p.P151T and *ARID1A* p. G779*) were only found in the neoplastic T cells, presumably representing later mutations in PTCL-NOS development following acquisition of the *TET2* and *SETX* mutations.

Fig. 3: three AITL cases with concurrent hematologic neoplasm

Patient #5 was initially diagnosed as AITL, followed by a diagnosis of chronic myelomonocytic leukemia (CMML) 7 months later. In the BM specimen, taken four months prior to the diagnosis of CMML and sequenced in this study, the overall pathologic findings showed 1-5% involvement by AITL and suspected involvement by a myeloid neoplasm. Three identical mutations, including 2 *TET2* and one *DNMT3A* mutations: p.I274delinsISfs, p.L1830* and p.W893S alterations, respectively, were identified in both the LN and BM with high allele burdens (VAF range, 25-50%, **Fig. 3A**, **Suppl. Table 3**). In addition, pathogenic *SRSF2* and *JAK2* mutations were identified in the BM. These findings support a scenario in which AITL and CMML arose via divergent evolution from a common HSC clone mutated in the CH-associated *TET2* and *DNMT3A* genes. Subsequent development involves accumulation of additional mutations: *SRSF2* and *JAK2* mutations to AITL.

Patient #20 was initially diagnosed with PV and progressed to post-PV PMF after 10 years. Two months later, the patient was also diagnosed with AITL. We sequenced the T-cell lymphoma in the LN and the paired bone marrow specimen with post-PV PMF (the initial PV specimen was unavailable). The overall pathologic studies showed no lymphoma involvement in the BM. The NGS sequencing revealed that the T and myeloid malignant cells harbored two identical destructive *TET2* mutations with high mutant allele burdens, p. Q939* (20% VAF) and p. E1026delinsXDfs (42% VAF). The driver mutation for MPN, *JAK2* p.V617F, was not only present in the post-PV PMF (88% VAF), but also found in the concomitant AITL with the mutant allele burden of 54.5% (Fig. 3B, Suppl. Table 3). No *IDH2* or *RHOA* mutation was detected in the AITL. These findings suggest that the *JAK2* driver mutation was acquired early in the HSC. Indeed, *JAK2* mutation was thought to be an early event in PV⁻¹. In this particular case, the combination of *TET2* and *JAK2* V617F may also be sufficient to drive AITL development, as no other drivers like *IDH2* or *RHOA* were found.

Patient #14 initially presented as immune thrombocytopenia (ITP) and had a splenectomy in 2008. He was diagnosed with AITL two years later and DLBCL about 7 years later. We sequenced two diagnostic tissue samples for the AITL and DLBCL, respectively, as well as one BM sample collected from this patient in 2010. The morphologic, immunophenotyping and molecular findings confirmed that the BM sample was not involved by AITL or a myeloid neoplasm. Interestingly, two nonsense *TET2* mutations, p.K454* and p.K1799*, were identified in all three samples with the VAFs ranging from 32% to 51%. An additional pathologic mutation *EZH2*, p. Y646S, was detected only in the DLBCL (**Fig. 3C, Suppl. Table 3**). The results from this patient suggest that the mutated HSC clone, harboring *TET2* p.K454* and p.K1799* alterations, differentiates into progeny cells of three different lineages (myeloid, T lymphoid, B lymphoid), each of which gives rise to CH, or transformed to AITL or DLBCL. The additional *EZH2* mutation has been reported in B-cell lymphomas^{2,3} and likely plays a role in the DLBCL development.

Method

Patients and Study Samples

All tissue samples (27 lymph node tissue specimens, 27 bone marrow aspirate/peripheral blood samples) were collected from 25 AITL or 2 PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019 following World Health Organization classification criteria by attending hematopathologists at NYP/Weill Cornell Medical Center, and clinical Information was obtained from electronic clinical records. Of these 27 study cases, 4 were initially diagnosed with PTCL with THF phenotype (**Suppl. Table. 1**), and included as the part of the AITL cases according to their similar clinical and molecular features as recently proposed by WHO⁴. This study was conducted in accordance with the Declaration of Helsinki regulations of the protocols approved by the Institutional Review Board of Weill Cornell Medicine, New York, USA. Written consent for use of the samples for research was obtained from patients or their guardians.

Genomic DNA was extracted from lymph node tissue and bone marrow or PBMC cell pellets following manufacturer's instructions (QIAamp DNA Mini Kit, Qiagen, Germantown). DNA samples and sequencing libraries used in targeting sequencing as described below were quantitated by Tape Station (Agilent Technologies, Santa Clara) and Qubit (Thermo Fisher Scientific, Singapore).

T Cell Targeted Sequencing

A 538 gene targeted sequencing panel were designed to investigate the genomic profile of the primary tumors and the BM/PB tissues⁵. The genomic regions covered by sequencing include coding exons and splice sites of these genes (target region: \sim 3.2 Mb) that were reported being recurrently mutated (>2) in mature T-cell neoplasms, as well as genomic regions corresponding to recurrent translocations. Using an input of genomic DNA of at least 100 ng isolated from frozen tissues or FFPE samples, the next-generation sequencing (NGS) libraries were constructed using

the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA), according to the manufacturer's protocols. Multiplexed libraries were sequenced using 150-bp paired end Hiseq4000 sequencers (Illumina, San Diego, CA, USA). NEXTGENe software (Softgenetics, State College, PA, USA) was used to perform bioinformatic analysis (SNV and INDEL variant calls) with standard settings recommended by the manufacturer. Specifically, cutoff values for the variant allele frequency, population frequencies, and strand bias were set at 5%, 0.01%, and 1:5, respectively.

Myeloid NGS Panel

Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel⁶. The primers target coding exons of the genes, leading to a total of 726 amplicons. Libraries were prepared by microdroplet-based PCR target enrichment method from DNA, followed by sequencing using the Illumina MiSeq yielding 260-bp paired end reads. Sequencing data were analyzed and reported with a customized analytical pipeline. This NGS panel testing is performed in a clinical lab CLIA-certified and accredited by the College of American Pathologists.

Data Analysis

Data analysis were conducted with GraphPad/Prism 5 software and various R packages, including base packages, ggplot2, ComplexHeatmap and Maftools. The survival comparison was analyzed using Kaplan-Meier curves (log-rank test, significance defined as p < 0.05).

Supplemental figure legend

Suppl. Fig. 1. AITL variants involving BM/PB. (A) Venn diagram illustrates the distribution of the shared, and the LN or BM/PB-specific mutations. Note that the variants detected in the BM/PB due to lymphoma involvement are included in this diagram, in contrast to Fig. 1B presented in the main text. (B) The type of variants and mutation frequencies (relative to the total number of cases) for the top 6 mutated genes identified in AITL/PTCL-NOS and matched BM/PB are shown. Different colors represent variant classifications as indicated. (C) Heat map showing the mutations detected in the BM/PB samples in each case. Only the major recurrent mutations are listed. The tumor burden (TB) in the BM/PB was estimated based on morphologic and immunophenotypic and molecular assessment, and the predicted CH status (determined based on comparison of the VAF of the mutations with TB) is indicated. Blue rectangles highlight the VAFs of the variants due to AITL involvement. CH, clonal hematopoiesis; +, presence of CH; -, absence of CH; \$, mutation in *STAT3*; ^, mutation in *DDX11*. (D) Dot plot comparing VAFs of the CH-associated variants and those related to lymphoma involvement in the BM/PB specimens. Mean \pm SEM of the VAFs is shown for each subgroup. (E) The proportion of the cases with or without BM or PB involvement by the neoplastic T cells (IVS), or with/without clonal hematopoiesis (CH), respectively, is summarized.

Suppl. Fig.2 Overall and lymphoma-specific genomic alterations in primary AITL/PTCL-NOS. (A) Mutation plot showing the overall mutation profile in the LN tissues involved by AITL./PTCL-NOS. (B) Mutation plot showing the AITL/PTCL-NOS-specific mutations identified in lymphoma samples after excluding the CH-associated variants. Top bars on each plot indicate the numbers of variants detected per sample. The percentage at right shows the gene mutation frequency in the cohort of the patients. Sample IDs are indicated at the bottom of each plot. Variant classifications are indicated with different colors.

Suppl. Fig.3 Overall and CH-related genomic alterations in the matched BM/PB samples. (A) The overall mutation profile in the BM/PB shown. (B) The CH–related mutation profile identified in the BM/PB is shown after excluding the variants due to AITL involvement. Top bars on each plot indicate the numbers of the variants detected per sample. The percentage showing gene mutation frequency in the patient cohort is shown at the right. Sample IDs are indicated at the bottom of each plot. Variant classifications are indicated with different colors.

Suppl. Fig. 4 Comparison of VAFs of the variants found in paired AITL and BM/PB samples. Red color highlights the CH-associated variants shared between the LN and BM/PB compartments. The black circles indicate variants specific to the lymphomas, the pink circles represent mutations specific to BM/PB. Cases that were not presented in Fig. 1 and Fig. 3 are shown in this figure. In Pt #7, three mutations specific to BM were found in PLCG1, ACSL3 and CTTNBP2. These may represent novel CH-associated mutations. In Pt #8, DNMT3A p.W330*, likely


representing a minor CH clone, was also found specifically in the BM. In Pt.#24, an additional ASXL1 frameshift mutation was identified in the BM, which showed hypercellularity with increased granulopoiesis. In this patient, we appeared to capture the acquisition of a subclonal *JAK2* V617F mutation during tumor progression, which was identified by the myeloid panel in the purified granulocytes from the PB but not detected in the BM one year before (#24).

Suppl. Fig. 5. Summary of all CH-associated and non-CH-associated mutations identified in AITL/PTCL, NOS and their matched BM/PB. Pt#, Patient ID.

Reference

- 1. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. *Blood*. 2006;108(1):346-352.
- 2. Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. *Cancer Cell*. 2013;23(5):677-692.
- 3. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet*. 2010;42(2):181-185.
- 4. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.
- 5. Fiore D, Cappelli LV, Zumbo P, et al. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. *Cancers (Basel)*. 2020;12(6).
- Cheng S, Singh K, Liu YC, Kluk MJ, Hassane DC, Tam W. Targeted sequencing of recurrently mutated genes in myeloid neoplasms using the Raindance Thunderstorm-Illumina Miseq Platform: My Heme (Myeloid Hematologic Malignancy) Panel. the Association for Molecular Pathology (AMP) 2017 Annual Meeting. Vol. 19: The Journal of Molecular Diagnostics; 2017:962.

Suppl. Fig. 1



#28 -

#29 -

0

0.1

0

0

0

35.6

0.56

0




1-5% +

P < 0.0001 75-50 L 50 T 40 10-8800 2-0 1-▲▲▲ СН **Tumor variants** by involvement Variants (n =44) (n=37)


30

n

BM/PB



Suppl. Fig.2



- Frame_Shift_Del Frame_Shift_Ins
- Missense_Mutation Splice_Site
- Nonsense_Mutation = In_Frame_Del
- In_Frame_Ins Multi_Hit

В


Suppl. Fig.3

Α

Overall genomic alterations (paired BM/PB, n =25)


Altered in 25 (100%) of 25 samples. 18 -TET2 76% 36% 28% 12% 12% 8% RHOA DNMT3A IDH2 PLCG1 JAK2 TTN 8% VAV1 8% ACSL3 ASXL1 ATP1A3 4% Filtering out the variants by 4% 49 lymphoma involvement CDHR4 4% CREB3L1 496 CSMD3 49 CTNNB1 4% CTTNBP2 4% DDX11 4% DLGAP3 GNAI2 4% GRID2 4% JAK3 4% LAMA2 4% MAPK3 49 PCDH17 4% PHF6 4% PIK3R1 4% POT1 4% RUNX1T1 4% SETX 49 SFSR2 4% STAT3 4% SYNE1 TP53 ZZEF1 4% 4% 4% Pair2,58M Pair2,58M Pair2,58M Pair2,58M Pair5,58M Pair5,58M Pair5,58M Pair15,58M Pair15,58M Pair15,58M Pair16,58M Pair16,58M Pair16,58M Pair16,58M Pair16,58M Pair16,58M Pair16,58M Pair16,58M

CH-associated genomic alterations (Paired BM/PB, n =19)




- Frame_Shift_Del Frame_Shift_Ins
- Missense_Mutation Splice_Site
- Nonsense_Mutation = In_Frame_Del
- In_Frame_Ins
 Multi_Hit


Suppl. Fig. 4 Comparison of VAFs of the variants found in paired AITL and BM/PB samples for each patient (Continued)



Suppl. Fig. 4 Comparing VAFs of the variants found in paired AITL and BM/PB samples for each patient (Continued)







Suppl. Fig. 5. Summary of individual mutations shared and unique in neoplastic T cells and untransformed myeloid tissues

| | - | sociate ations | <u>d</u> | Non-CH-associate | | | | |
|-------------------------|------|-------------------|----------|-----------------------------------|-------------------|----------|------------|--|
| Variants | LN | BM/ PB | Pt# | Variants | LN | BM PB | Pt# | |
| TET2 p.E1089fs | 36.9 | 48.4 | 1# | TET2 p.Q743* | 16.7 | 0 | 1# | |
| DNMT3A p.F701L | 27.6 | 34.6 | 1# | IDH2 p.R172T 50% RHOA p.G17V | 20.5 | 0 | 1# 1# | |
| | | | | STAT3 p.W474* | 18.3 | 0 | 2# | |
| STAT3 p.Y657_K658insALL | 21.6 | 8.3 | 2# | IDH2 p.R172G TET2 p.S1612Lfs | 8.8 7.3 6.3 | 0 | 4# 4# | |
| TET2 p.P1367R | 27 | 20.3 | 3# | DLGAP3 p.G85Vfs RHOA p.G17V | 6.3 5.5 | 0 | 4# 4# | |
| TET2 p.Y1337* | 25 | 16 | 3# | TET2 p.R1167K | 5.1 | 0 | 4# | |
| ATP1A3 p.V216M | 11.4 | 4.5 | 4# | CD28 p.T195P CDHR4 p.V647L | 7.3 | 0 | 5# 5# | |
| DNMT3A p.Q678* | 2 | | | 0% IDH2 p.R172S NRG1 p.P174L | 7.1 8.7 | 0 | 5# 5# | |
| | | 6.2 | 4# | RHOA p.G17V | 7.8 | 0 | 5# | |
| DNMT3A p.W893S | 36.1 | 48.2 | 5# | RHOA p.G17V CHSY3 p.R375W | 6.3 13.1 | 0 | 6# 7# | |
| TET2 p.l274fs | 32.1 | 42.8 | 5# | CREB3L1 p.P187T | 20.2 | 0 | 7# | |
| TET2 p.L1830* | 25.7 | 34.3 | 5# | CSMD3 p.H1786N CTNNB1 p.T41A | 14.1 20.9 | 0 | 7# 7# | |
| TET2 p.Y1679fs | | | | GNAI2 p.G45R GRID2 p.N52Y | 25.6 13.5 | 0 | 7# 7# | |
| | 12.6 | 0.4 | 6# | LAMA2 p.G2202S | 19 | 0 | 7# | |
| TET2 p.S315fs | 32.2 | 43.4 | 8# | MAPK3 p.D338E PCDH17 p.V1117A | 39.6 20 | 0 | 7# 7# | |
| DNMT3A p.R771N | 36 | 45 | 8# | POT1 p.T105K | 18.3 | 0 | 7# | |
| 68% TET2 p.D1376G | 16.9 | 0.3 | 10# | RHOA p.G17A SYNE1 p.M5804T | 20.5 | 0 | 7# 7# | |
| TET2 p.N1484K | | | | TTN p.E28924A TTN p.P12842T | 18.1 | 0 | 7# 7# | |
| | 47.3 | 39.3 | 10# | VAV1 p.R798Q | 19.8 | 0 | 7# | |
| TET2 p.K454* | 34.5 | 32.7 | 14# | ZZEF1 p.D1205V ACSL3 p.Q419Lfs | 23.1 | 0 8.7 | 7# 7# | |
| TET2 p.K1799* | 35.9 | 51.5 | 14# | CTTNBP2 p.N442N | 0 | 13.7 | 7# | |
| TET2 p.Q705* | 28.7 | 44.7 | 15# | TET2 c.3594+1G>A TET2 p.Q622* | 14.6 15.7 | 0 | 8# 9# | |
| 0% PHF6 p.K132fs | | | | RHOA p.G17V DOCK7 p.P240S | 15 11.2 | 0 | 9# | |
| | 2.6 | 16.9 | 15# | TET2 p.V415fs | 16.6 | 0 | 9# 10# | |
| DNMT3A p.G413fs | 5.3 | 10.9 | 16# | RHOA p.G17V IDH2 p.R172T | 10.9 10 | 0 | 10# | |
| SETX p.Y2258D | 41.5 | 2 | 18# | RHOA p.G17V | 6.4 | 0 | 11# | |
| TET2 c.3501-1G>A | 30.3 | 3 | 18# | DNAH5 p.V2638L IDH2 p.R172K | 8.1 7.8 | 0 | 11# 11# | |
| DDX11 p.L659fs | 6.2 | | | RUNX1T1 p.V286A TET2 p.Q626* | 10.5 | 0 | 12# 12# | |
| | | 8.4 | 19# | TET2 p.N1346del | 12.4 | 0 | 12# | |
| TET2 p.Q574* | 25.9 | 0.6 | 22# | VAV1 p.G811R RHOA p.G17V | 18.4 6.7 | 0 | 12# | |
| TET2 p.G1861V | 13.9 | 41.1 | 24# | RHOA p.G17V | 21.2 20.4 | 0 | 17# | |
| TTN p.W25027* | 12.2 | 43 | 24# | TET2 p.Q1274* TET2 p.Y1589* | 24.1 | 0 | 17# 17# | |
| TET2 p.S1607* | 11.1 | 43.7 | 24# | TP53 p.P151T ARID1A p.G779* | 47.4 | 0 | 18# 18# | |
| TET2 p.Y1255Dfs | | | | BCOR p.W191* | 5.1 | 0 | 18# | |
| | 21.4 | 23.1 | 25# | TP53 p.G244D PLCG1 p.R748S | 7.8 | 0 | 22# 22# | |
| DNMT3A p.L500Sfs | 6.3 | 0.2 | 25# | RHOA p.G17V IDH2 p.R172K | 18 9.2 | 0 | 22# 23# | |
| PTPRZ1 p.D1426fs | 68.3 | 65 | 26# | RHOA p.G17V | 11.2 | 0 | 23# | |
| JAK3 p.A746V | 10.3 | 14.7 | 28# | TET2 p.K1299fs RHOA p.G17V | 23.7 5.5 | 0 | 23# 25# | |
| TET2 p.C1273S | 5.9 | 5.5 | 28# | PIK3R1 p.K587KE IDH2 p.R172G | 15.6 10.1 | 0 | 26# 28# | |
| - | | | | TET2 p.R1216* | 7.8 | 0 | 28# | |
| TET2 p.H1817fs | 6.4 | 10.9 | 28# | PLCG1 p.S520F RHOA p.G17VG | 12.5 | 0 | 29# 29# | |
| DNMT3A p.R882H | 46 | 35.6 | 29# | TET2 p.L1111* | 11.8 | 0 | 29# | |
| | 1 | 1 | - | TET2 p.C1211fs | 12,4 | Q | 29# | |

| No. | Patient ID | Type of Specimens | Sex | Age | Dx | Pathology of BM/PBL | Concurrent hematologic Malignancy | Morphology | MFC | TCRG Rearrangement | тв |
|-----|------------|-------------------------|-----|-----|--------------------------------------|--|---|------------|-------|-----------------------|--------------------|
| 1 | #1 | BM | F | 58 | Lung cancer, AITL | megakaryocytes slightly increased in number without significant cytologic atypia. PBL, Normocytic anemia. Leukocytosis with neutrophilia | No | + | 0.5% | n/a | 0.5% |
| 2 | #2 | PBL | м | 33 | PTCL, NOS | BM, hypocellular bone marrow with relative eosinophilia, PBL, eosinophilia | No | - | 1.50% | PCR+ | 1.5% |
| 3 | #3 | PBL | м | 51 | AITL | unremarkable | No | - | 0 | PCR- | 0.0% |
| 4 | #4 | BM | F | 65 | AITL | involvement, megakaryocytes are focally clustered and some have atypical nuclear lobation, PBL, unremarkable | No | + | 2.10% | PCR+ | 2.1% |
| 5 | #5 | BM | F | 65 | AITL | granulopoiesis, dysgranulopoiesis, decreased erythropoiesis, monocytosis, unremarkable T cells. PBL, Absolute monocytosis. | CMML, 10 months post-AITL Dx | - | 0 | PCR+ | 1-5% ^{\$} |
| 6 | #6 | PBL | м | 75 | AITL | Megakaryocytes were dysplastic (>10%). Including small / giant forms with hypo / hyperlobulated nuclei. Myelopoiesis is hyperplastic and slightly left-shifted. Mild dysgranulopoiesis is present (<10%) with giant forms and abnormal segmentation. | No | - | 0 | n/a | 0.0% |
| 7 | #7 | BM | м | 70 | AITL | involvement | No | + | 4% | n/a | 4.0% |
| 8 | #8 | BM | м | 72 | Prostate cancer, PTCL-TFH | involvement | No | + | 0.10% | n/a | 0.1% |
| 9 | #9 | BM | F | 53 | AITL | unremarkable | No | - | 0 | PCR+ | 1-5% ^{\$} |
| 10 | #10 | BM | м | 63 | AITL | unremarkable | No | - | 0 | PCR- | 0.0% |
| 11 | #11 | BM | F | 70 | AITL | ITP | No | - | 0 | PCR- | 0.0% |
| 12 | #12 | PBL | м | 75 | AITL | unremarkable | No | - | 0 | PCR+ | 1-5% |
| 13 | #14 | BM | м | 77 | PTCL-TFH, DLBCL | ITP | DLBCL, 7 years post-AITL Dx | - | 0 | PCR- | 0.0% |
| 14 | #15 | BM | м | 76 | AITL | unremarkable | No | - | 0 | PCR+ | 1-5% ^{\$} |
| 15 | #16 | BM | F | 84 | AITL | involvement | No | + | 10% | PCR+ | 10.0% |
| 16 | #17 | PBL | м | 80 | AITL | | No | - | 0.40% | PCR+ | 0.4% |
| 17 | #18 | BM | м | 63 | PTCL, NOS | Mildly hypercellular marrow with mild granulocytic hyperplasia | No | - | 0 | PCR- | 0.0% |
| 18 | #19 | BM | F | 53 | AITL | unremarkable | No | - | 0 | PCR+ | 1-5% ⁵ |
| 19 | #20 | BM | м | 45 | Lung Cancer, post-PV MF, PTCL-TFH | post-PV myelofibrosis | PV, post-PV myelofibrosis prior to AITL Dx | - | 0 | PCR- | 0.0% |
| 20 | #21 | BM | F | 42 | AITL | unremarkable | No | - | 0 | PCR- | 0.0% |
| 21 | #22 | BM | F | 63 | AITL | a mildly hypercellular bone marrow with myeloid hyperplasia | No | - | 0 | PCR- | <1% |
| 22 | #23 | BM | м | 65 | DLBCL and AITL | unremarkable | DLBCL | + | 10% | PCR+ | 10.0% |
| 23 | #24 | BM | м | 38 | AITL | Myelopoiesis is hyperplastic and slightly left-shifted with ~4% blasts. Evidence of significant dysplasia is not seen | No | - | 0 | PCR- | 0.0% |
| 24 | #25 | BM | м | 70 | AITL | Hypercellular bone marrow with myeloid hyperplasia | No | - | 0 | PCR- | 0.0% |
| 25 | #26 | BM | м | 63 | PTCL-TFH | involvement | No | + | 2.10% | PCR+ | 2.1% |
| 26 | #27 | no matched BM or PBL | F | 67 | Lung cancer, PTCL, NOS | n/a | n/a | n/a | n/a | n/a | n/a |
| 27 | #28 | BM | F | 79 | AITL | involvement | No | + | 2.40% | PCR+ | 2.4% |
| 28 | #29 | BM | м | 58 | CTCL to AITL | small population of abnormal myeloid blasts noted in BM, but no MPN diagnosized | No | - | 0 | PCR+ | 1-5% ^{\$} |

Ptt, Patient ID, T, type of specimen, HP, histopathology IM, immunophenotyping, MP, molecular pathology testing TB, neoplastic T cell burden by BM involvement CH, clonal hematopoisis IC, suspicious but inconclusive S limit of detection of TCRG (15%) rv/a, data unavailable DLBCL, diffuse large B cell lymphoma CMML, Chronic Myelomonocytic Leukemia PCR+, monoclonal TCR rearrangement ATL1, angioimmuoblastic T-cell lymphoma PTCL, peripheral T-cell lymphoma CFCL, custances T-cell lymphoma MF, myelofibroais MCF, multiple color flow cytometry

| | | Pr | imary AITL | . lymphoma | a | Paired BM/PBL ^{\$} | | | |
|----------------------|-------------------|---------|------------|------------|---------|-----------------------------|-------|--------|---------|
| | | summary | Mean | Median | Percent | summary | Mean | Median | Percent |
| | Frame_Shift_Del | 9 | 0.333 | 0 | 8.82 | 6 | 0.316 | 0 | 13.64 |
| | Frame_Shift_Ins | 7 | 0.259 | 0 | 6.86 | 7 | 0.316 | 0 | 15.91 |
| Variant | In_Frame_Del | 1 | 0.037 | 0 | 0.98 | 0 | 0 | 0 | 0.00 |
| | In_Frame_Ins | 1 | 0.037 | 0 | 0.98 | 1 | 0.053 | 0 | 2.27 |
| Classification | Missense_Mutation | 62 | 2.296 | 1 | 60.78 | 17 | 0.789 | 1 | 38.64 |
| | Nonsense_Mutation | 20 | 0.741 | 1 | 19.61 | 12 | 0.579 | 0 | 27.27 |
| | Splice_Site | 2 | 0.074 | 0 | 1.96 | 1 | 0.053 | 0 | 2.27 |
| Total | | 102 | 3.778 | 3 | 100.00 | 44 | 2.105 | 2 | 100.00 |
| No. of Samples | | 27 | | | | 27* | | | |
| No. of Mutated genes | | 37 | | | 14 | | | | |

Supplemental Table 2 Variant summary

*A total of 23 bone marrow and 4 PBL samples were sequenced. Among 27 BM/PB samples, 20 had identifiable mutated genes after filtering out the variants involved.

 $^{\$}$ the variants from the invovled lymphoma excluded

| Supplemental Table3 Individival mutations and their VAFs in the lymphoma cases and matched BM/PB | |
|--|--|

| No. of Patient ID | | Dx | Mutations | Alt% in lymphoma (LN) | Alt% in BM or PBL | Purified granulocytes from PB of AITL patients | Note | |
|-------------------|-------------|-------------------|--------------------------------|-----------------------|-------------------|--|------|--|
| 1 | Patient 1# | Lung cancer, AITL | TET2 p.E1089fs | 36.87 | 48.39 | | | |
| | | | DNMT3A p.F701L | 27.59 | 34.62 | | | |
| | | TET2 p.Q743* | 16.69 | 0.43 | | | | |
| | | | IDH2 p.R172T | 20.47 | 0.00 | | | |
| | | | RHOA p.G17V | 14.17 | 0.43 | | | |
| 2 | Patient 2# | PTCL, NOS | STAT3 p.Y657_K658insALL | 21.61 | 8.34 | | | |
| | | , | STAT3 p.W474* | 18.33 | 2 | | | |
| 3 | Patient 3# | AITL | TET2 p.P1367R | 27.04 | 20.26 | | | |
| | | | TET2 p.Y1337* | 24.97 | 16.03 | | | |
| 4 | Patient 4# | AITL | ATP1A3 p.V216M | 11.38 | 4.47 | | | |
| | | / = | IDH2 p.R172G | 8.81 | 1.27 | | | |
| | | | TET2 p.S1612Lfs | 7.34 | 0 | | | |
| | | | DLGAP3 p.G85Vfs | 6.27 | 1.52 | | | |
| | | | RHOA p.G17V | 5.53 | 0.68 | | | |
| | | | | 5.11 | 0.82 | | | |
| | | | TET2 p.R1167K | 1.95 | 6.22 | | | |
| _ | | | DNMT3A p.Q678* | | | | | |
| 5 | Patient 5# | AITL | CD28 p.T195P | 7.32 | 0.00 | | | |
| | | | CDHR4 p.V647L | 10.15 | 0.28 | | | |
| | | | DNMT3A p.W893S | 36.08 | 48.19 | | | |
| | | | IDH2 p.R172S | 7.08 | 0.23 | | | |
| | | | JAK2 p.V617F | 0.00 | 3.00 | | | |
| | | | SRSF2 | 0.00 | 28.00 | | | |
| | | | NRG1 p.P174L | 8.70 | 0.00 | | | |
| | | | RHOA p.G17V | 7.79 | 0.00 | | | |
| | | | TET2 p.I274delinsISfs | 32.13 | 42.79 | | | |
| | | | TET2 p.L1830* | 25.66 | 34.32 | | | |
| 6 | Patient 6# | AITL | TET2 p.Y1679delinsYTfs | 12.6 | 0.39 | | | |
| - | | | RHOA p.G17V | 6.28 | 0.00 | | | |
| 7 | Patient 7# | AITL | CHSY3 p.R375W | 13.06 | 0 | | | |
| 7 Fallent 1# | 1 aucrit 1# | | CREB3L1 p.P187T | 20.21 | 0.34 | | | |
| | | CSMD3 p.H1786N | 14.13 | 0.46 | | | | |
| | | CTNNB1 p.T41A | 20.86 | 0.40 | | | | |
| | | | | | | | | |
| | | | GNAI2 p.G45R | 25.62 | 0.34 | | | |
| | | | GRID2 p.N52Y | 13.51 | 0.57 | | | |
| | | | LAMA2 p.G2202S | 18.97 | 0.74 | | | |
| | | | MAPK3 p.D338E | 39.61 | 0.743034056 | | | |
| | | | PCDH17 p.V1117A | 19.96 | 0.239616613 | | | |
| | | | PLCG1 p.S345F | 0 | 0.175284838 | | | |
| | | | POT1 p.T105K | 18.3 | 1.080351114 | | | |
| | | | RHOA p.G17A | 20.48 | 0.116009281 | | | |
| | | | SYNE1 p.M5804T | 19.46 | 0.347912525 | | | |
| | | | TTN p.E28924A | 18.11 | 0.636942675 | | | |
| | | | TTN p.P12842T | 11.4 | 0.401854714 | | | |
| | | | VAV1 p.R798Q | 19.81 | 0.421545667 | | | |
| | | | ZZEF1 p.D1205V | 23.15 | 0.443951165 | | | |
| | | | ACSL3 p.Q419Lfs | 0 | 8.66 | | | |
| | | | CTTNBP2 p.N442N | 0 | 13.66204417 | | | |
| 8 | Patient 8# | Prostate cancer | TET2 p.S315fs | 32.17 | 43.37349398 | | | |
| - | | PTCL-TFH | TET2 c.3594+1G>A | 14.64 | 2.605459057 | | | |
| | | | DNMT3A p.Arg771Gln | 36 | 45 | | | |
| | | | DNMT3A p.Trp330* | 0 | 1.66 | | | |
| 9 | Patient 9# | AITL | TET2 p.Q622* | 15.65 | 0 | | | |
| 3 | r audill 9# | | RHOA p.G17V | 15.04 | 0 0.241400121 | | | |
| | | | | | 0.241400121 | | | |
| 10 | D-# | A 171 | DOCK7 p.P240S | 11.19 | 0.04540005 | | | |
| 10 | Patient 10# | AITL | TET2 p.D1376G | 16.89 | 0.31512605 | | | |
| | | | TET2 p.V415fs | 16.62 | 0 | | | |
| | | | RHOA p.G17V | 10.92 | 0 | | | |
| | | | IDH2 p.R172T | 10.02 | 0 | | | |
| | | | TET2 p.N1484K | 47.33 | 38.26 | | | |
| 11 | Patient 11# | AITL | RHOA p.G17V | 6.36 | 0 | | | |
| | | | DNAH5 p.V2636L | 8.12 | 0 | | | |
| | | | IDH2 p.R172K | 7.75 | 0 | | | |
| 12 | Patient 12# | AITL | RUNX1T1 p.V286A | 10.49 | 0 1.11 | | | |
| 14 | | | TET2 p.Q626* | 11.17 | 1.25 | | | |
| | | | TET2 p.0020 TET2 p.N1346del | 12.4 | 2.29 | | | |
| | | | | | | | | |

| 13 F | Patient 14# | PTCL-TFH | TET2 p.K454* | 34.50 | 32.71 | | 41.8 ^{&} |
|------|-------------|-----------------------|---------------------------------|---------------|-------------------|------|--|
| | | DLBCL | TET2 p.K1799* EZH2 p.Y646S | 35.94 0.00 | 51.49 0.00 | | 33.6 ^{&} 29.9 ^{&} |
| 14 | Patient 15# | AITL | TET2 p.Q705* | 28.68 | 44.65 | | 20.0 |
| | | | PHF6 p.K132fs | 2.56 | 16.94 | | |
| 15 | Patient 16# | AITL | DNMT3A p.G413fs | 5.30 | 10.85 | | |
| | | | RHOA p.G17V | 6.68 | <mark>5.21</mark> | | |
| 16 | Patient #17 | AITL | RHOA p.G17V | 21.2 | <mark>0.44</mark> | | |
| | | | TET2 p.Q1274* | 20.44 | <mark>0.24</mark> | | |
| | | | TET2 p.Y1589* | 24.14 | <mark>0.66</mark> | | |
| 17 | Patient #18 | PTCL, NOS | ARID1A p.G779* | 14.08 | 0 | | |
| | | | SETX p.Y2258D | 41.47 | 2 | | |
| | | | TET2 c.3501-1G>A | 30.3 | 3 | | |
| | | | TP53 p.P151T | 47.38 | 0 | | |
| 18 | Patient #19 | AITL | DDX11 p.L659Cfs | 6.24 | 8.39 | | |
| 19 | Patient #20 | Lung Cancer | TET2 p.Q939* | 36.59 | 42.29 | | |
| | | post-PV MF | TET2 p.E1026delinsXDfs | 19.64 | 39.37 | | |
| | | PTCL-TFH | JAK2 p.V617F | 54.48 | 88 | | |
| 20 | Patient #21 | AITL | BCOR p.W191* | 5.1 | 0 | | |
| 21 | Patient #22 | AITL | RHOA p.G17V | 17.99 | <mark>0.82</mark> | | |
| | | | TET2 p.Q574* | 25.85 | 2.25 | | |
| | | | TP53 p.G244D | 7.83 | <mark>0.52</mark> | | |
| | | | PLCG1 p.R748S | 11.51 | 0.33 | | |
| 22 | Patient #23 | DLBCL | IDH2 p.R172K | 9.17 | 4 | | |
| | | AITL | RHOA p.G17V | 11.17 | 4 | | |
| | 5 | A 1777 | TET2 p.K1299delinsXVfs | 23.69 | <mark>5.64</mark> | | |
| 23 | Patient #24 | AITL | TET2 p.G1861V | 13.9 | 41.07 | 39.3 | |
| | | | TTN p.W25027* | 12.17 | 43 | n/a | |
| | | | TET2 p.S1607* | 11.12 | 43.65 0 | 32.6 | |
| | | | JAK2 p.V617F | 0 0 | 36 | 8.7 | |
| 24 | Patient #25 | Prostate cancer | ASXL1 p.G646Wfs*12 | 6.29 | 0.24 | 28.6 | |
| 24 | Patient #25 | Prostate cancer HL | DNMT3A p.L500Sfs RHOA p.G17V | 6.29 5.5 | 0.24 | | |
| | | AITL | TET2 p.Y1255Dfs | 21.44 | 23.08 | | |
| 05 | D // / //00 | | 1 | | | | |
| 25 | Patient #26 | PTCL-TFH | PIK3R1 p.K567KE | 15.61 | <mark>1.33</mark> | | |
| 26 | Patient #27 | PTCL, NOS | LRP1B p.L2470* | 1 | n/a | | |
| | | Lung cancer | STAT3 p.E616G | 6.55 | n/a | | |
| | | | TET2 p.K1254* | 18.51 | n/a | | |
| | | | TET2 p.C1289F | 17.36 | n/a | | |
| | | | | | | | |
| | | | SYNE1 c.4977-2delA | 20.88 | n/a | | |
| | | | VAV1 p.D797DV | 29.85 | n/a | | |
| 27 | Patient #28 | AITL | IDH2 p.R172G | 10.14 | 0 | | |
| | | | JAK3 p.A746V | 10.34 | 14.71 | | |
| | | | TET2 p.R1216* | 7.75 | 0 | | |
| | | | TET2 p.C1273S | 5.94 | 5.47 | | |
| | | | TET2 p.H1817delinsTQfs | 6.43 | 10.89 | | |
| 28 | Patient 29# | AITL | PLCG1 p.S520F | 12.52 | <mark>0.19</mark> | | |
| | | | RHOA p.G17VG | 10.86 | <mark>0.1</mark> | | |
| | | | TET2 p.L1111* | 11.82 | <mark>0.56</mark> | | I |
| | | | TET2 p.C1211delinsLFfs | 12.37 | 0 | | |
| | I | | DNMT3A p.R882H | 46 | 35.6 | | |

LN, lymph node BM, bone marrow

PBL, peripheral blood

VAF, variant allele frequency DLBCL, diffuse large B cell lymphoma Vaf values highlighted in yellow represent those of the AITL mutations invovled in bone marrow Vaf values highlighted in pink represent those of the mutations found only in bone marrow ⁸ detected in DLBCL (renal tissue) by myeloid panel

^a detected in DLBCL (renal tissue) by myeloid panel n/a, no data available PV, polycythemia vera MF, myelofibrosis TFH, follicular T helper cell Alt%, alternate allele frequency Alt% highlighted in yellow represent those of the AITL mutations invovled in bone marrow Alt% highlighted in pink represent those of the mutations found only in bone marrow